ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibitors of nuclear poly(ADP-ribose) polymerase (PARP) enzymes (e.g., PARP-1) have improved clinical outcomes in ovarian cancer, especially in patients with BRCA1/2 gene mutations or additional homologous recombination (HR) DNA repair pathway deficiencies.
|
31594824 |
2020 |
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mechanisms of PARP inhibitor resistance in ovarian cancer.
|
31815769 |
2020 |
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
PARP inhibitors have transformed the management of advanced high-grade serous ovarian cancer.
|
31630846 |
2020 |
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Let-7e suppresses DNA damage repair and sensitizes ovarian cancer to cisplatin through targeting PARP1.
|
31722968 |
2020 |
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
PARP inhibitors (PARPi) represent a major advance in the treatment of ovarian cancer associated with defects in homologous recombination DNA repair (HRR), primarily due to mutations in BRCA genes.
|
30342021 |
2019 |
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Success for First-Line PARP Inhibition in Ovarian Cancer.
|
31591108 |
2019 |
ovarian neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients.
|
30551885 |
2019 |
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the past few years, the advent of PARP inhibitors has been a revolution in the management of ovarian cancer.
|
31335830 |
2019 |
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
PARP inhibitors in ovarian cancer.
|
30543930 |
2019 |
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
GnRH-R-Targeted Lytic Peptide Sensitizes <i>BRCA</i> Wild-type Ovarian Cancer to PARP Inhibition.
|
30926640 |
2019 |
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
PARP1 plays a crucial role in multiple biological processes and PARP1 activation contributes to the development of various inflammatory and malignant disorders, including lung inflammatory disorders, cardiovascular disease, ovarian cancer, breast cancer, and diabetes.
|
31500199 |
2019 |
ovarian neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Inhibitors of PARP, which is a DNA damage repair enzyme, have been approved for use in BRCA mutated cancers like breast and ovary cancer.
|
31303961 |
2019 |
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally, 3 new PARP inhibitors (olaparib, rucaparib, niraparib) have been approved for use in ovarian cancer, with different indications as maintenance therapy or treatment of recurrence.
|
31117037 |
2019 |
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Indeed, three PARP1 inhibitors (Olaparib, Rucaparib, and Niraparib) have recently been approved by the Food and Drug Administration for the treatment of ovarian cancer.
|
29327913 |
2018 |
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
|
29352572 |
2018 |
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer.
|
30540933 |
2018 |
ovarian neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The single agent activity of PARP inhibitors (PARPi) in germline BRCA mutated (gBRCAm) breast and ovarian cancer suggests untapped potential for this new class of drug in breast cancer.
|
29644491 |
2018 |
ovarian neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
|
29567272 |
2018 |
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
PARP inhibitors have been widely tested in clinical trials, especially for the treatment of breast cancer and ovarian cancer, and were shown to be highly successful.
|
29684820 |
2018 |
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
PARP Inhibitors in Ovarian Cancer.
|
29512470 |
2018 |
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.
|
29464354 |
2018 |
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey.
|
29871906 |
2018 |
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
We used a translational approach to describe the significance of PET imaging of PARP-1 in ovarian cancer.
|
29509546 |
2018 |
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we review the current therapeutic settings combining anti-angiogenesis inhibitors with chemotherapy, PARP inhibitors or immune checkpoint blockers, focusing on ovarian cancer as tumor model.
|
29703482 |
2018 |
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Olaparib (Lynparza™) is a PARP inhibitor approved for advanced BRCA-mutated (BRCAm) ovarian cancer.
|
30353044 |
2018 |